Arizona Tribune - Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of formulation enhancements using both DehydraTECH-semaglutide ("DHT-sema") glucagon-like peptide-1 ("GLP-1") compositions and DehydraTECH-CBD ("DHT-CBD") compositions to explore the potential for additional improved performance as well as stake new intellectual property ("IP") claims (the "Study").

Contracts with the CRO have been signed, materials sourcing is underway, and Study design is being finalized with the goal of beginning dosing within approximately 60 days.

"The global arms race in diabetes control, weight loss and other GLP-1-indicated areas of treatment is intensifying with recent new oral drugs being approved by the Food and Drug Administration ("FDA")," said Richard Christoper, CEO of Lexaria Bioscience. "With tens of billions of dollars in new annual revenue soon expected in the sector, there has never been a better time to stake new legal IP claims in order to offer the pharmaceutical industry improved performance including reducing side effects, while improving Lexaria's probabilities of becoming an indispensable provider of improved drug delivery technology."

While final design parameters of this Study are ongoing, it is expected to utilize Sprague-Dawley rats with 8 to 11 separate arms evaluating a number of different novel compositions. Blood samples will be taken at multiple timepoints through an 8-24-hour post-dosing period to quantify the pharmacokinetic performance of each composition. In addition, the Study will also measure drug concentrations in the brain since DehydraTECH has, in the past, evidenced apparent superior absorption of active ingredients into brain tissue, an area of intense interest due to the fact that GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry, thus making brain biodistribution vital. There will be one reference arm using an existing DHT-sema composition and another reference arm using an existing DHT-CBD composition. Lexaria intends to leverage the wealth of study data that we have amassed from previous work by utilizing our proprietary historical data and the reference arms as baseline comparators to the current Study results as we search for areas of superiority.

One of the novel objectives of this Study will be to evaluate alternative/additive formulations to SNAC (salcaprozate sodium) which is currently in use by Novo Nordisk® with their oral Rybelsus® and Wegovy® tablet products. If Lexaria is able to establish novel new formulations with superiority to SNAC, we may be able to register new patents and create valuable new proprietary IP and an industry alternative to SNAC that could be of interest within the keenly competitive GLP-1 sector.

Lexaria will update its stakeholders once dosing has begun. The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

View the original press release on ACCESS Newswire

H.Thompson--AT